Weekly updateCompaniesRecruiting servicePost a job
ALX Oncology

ALX Oncology

    Company info:

  • 1-50
  • 2015
  • San Francisco, CA
  • 100-500M



Claim company profile

About company:

ALX Oncology is developing immunotherapies for cancer treatment. CD47 is a cell surface protein expressed on cancer cells that signals to evade detection by the immune system. ALX’s approach revolves around inhibiting CD47 and the “don’t eat me” signal, known as checkpoint inhibition, to further stimulate the immune response against the cancer. The inhibitors are designed by ALX to have high affinity for CD47 and to avoid the limitations caused by hematologic toxicities seen in other immunotherapies. ALX believes their lead product candidate, evorpacept (ALX148), has a wide therapeutic window and can be combined with anti-cancer agents. Their current programs are focused on targeting CD47 across various oncology indications.


Claim company profile to post jobs directly on this page and this website.

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com